Author

Marissa Timothy

ORCID: 0000-0001-9257-2388

Observed ORCID: 0000-0001-9257-2388

OpenAlex ID: A5075768261

Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma.

2022 · Meredith McKean, David Henry Aggen, et al. · Journal of Clinical Oncology · 9

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma

2025 · David H. Aggen, Meredith McKean, et al. · Clinical Cancer Research · 7

IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.

2024 · David H Aggen, Meredith McKean, et al. · Journal of Clinical Oncology · 5

661 Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma

2022 · David Aggen, Meredith McKean, et al. · Regular and Young Investigator Award Abstracts · 4

Abstract CT268: Preliminary results from a first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors

2025 · Anthony W. Tolcher, Nehal J. Lakhani, et al. · Cancer Research · 2

Data from IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma

2026 · David H. Aggen, Meredith McKean, et al.

Supplementary Data1 from IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma

2026 · David H. Aggen, Meredith McKean, et al.

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

2025 · Guillermo Montalban-Bravo, Courtney DiNardo, et al. · Blood

A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.

2024 · Nehal J. Lakhani, Alexander I. Spira, et al. · Journal of Clinical Oncology

680 A phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer

2022 · Trupti Lingaraj, Marissa Timothy, et al. · Regular and Young Investigator Award Abstracts

392 A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma

2021 · Meredith McKean, Jason Luke, et al. · Regular and Young Investigator Award Abstracts

Works count: 11

Citation count: 27

H-index: 4

I10-index: